Corpus overview


Overview

MeSH Disease

Human Phenotype

Leukopenia (13)

Fever (10)

Lymphopenia (8)

Pneumonia (7)

Cough (4)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 13
    records per page




    Clinical characteristics of 134 convalescent patients with COVID-19 in Guizhou, China

    Authors: Siqin Zhang; Lin Liu; Bin Yang; Rou Li; Jianhua Luo; Jing Huang; Yanjun Long; Ying Huang; Jianping Zhou; Yan Zha; Xiangyan Zhang

    doi:10.21203/rs.3.rs-41986/v1 Date: 2020-07-13 Source: ResearchSquare

    Background: Previous studies have focused on the clinical characteristics of hospitalized patients with the novel 2019 coronavirus disease MESHD (COVID-19). Limited data are available for convalescent patients. This study aimed to evaluate the clinical characteristics of discharged COVID-19 patients.Methods: In this retrospective study, we extracted data for 134 convalescent patients with COVID-19 in Guizhou Provincial Staff Hospital from February 15 to March 31, 2020. Cases were analyzed on the basis of demographic, clinical, and laboratory data as well as radiological features. Results: Of 134 convalescent patients with COVID-19, 19 (14.2%) were severe cases, while 115 (85.8%) were non-severe cases. The median patient age TRANS was 33 years (IQR, 21.8 to 46.3), and the cohort included 69 men and 65 women. Compared with non-severe cases, severe patients were older and had more chronic comorbidities, especially hypertension HP hypertension MESHD, diabetes MESHD, and thyroid disease MESHD (P<0.05). Leukopenia HP Leukopenia MESHD was present in 32.1% of the convalescent patients and lymphocytopenia MESHD was present in 6.7%, both of which were more common in severe patients. 48 (35.8%) of discharged patients had elevated levels of alanine aminotransferase, which was more common in adults TRANS than in children TRANS (40.2% vs 13.6%, P=0.018). A normal chest CT was found in 61 (45.5%) patients during rehabilitation. Severe patients had more ground-glass opacity, bilateral patchy shadowing, and fibrosis MESHD. No significant differences were observed in the positive rate of IgG and/or IgM antibodies SERO between severe and non-severe patients.Conclusion: Leukopenia HP Leukopenia MESHD, lymphopenia HP lymphopenia MESHD, ground-glass opacity, and fibrosis MESHD are common in discharged severe COVID-19 patients, and liver injury MESHD is common in discharged adult TRANS patients. We suggest physicians develop follow-up treatment plans based on the different clinical characteristics of convalescent patients. 

    SEROPREVALENCE SERO AND CLINICAL SPECTRUM OF SARS-CoV-2 INFECTION IN MESHD THE FIRST VERSUS THIRD TRIMESTER OF PREGNANCY

    Authors: Francesca Crovetto; Fatima Crispi; Elisa Llurba; Francesc Figueras; Maria Dolores Gomez-Roig; Eduard Gratacos

    doi:10.1101/2020.06.17.20134098 Date: 2020-06-19 Source: medRxiv

    Introduction: Case registries of pregnant women diagnosed with coronavirus disease MESHD (COVID-19) by polymerase chain reaction (PCR) have reported that the majority experienced mild infection MESHD, but up to 9% may require critical care. Most COVID-19 cases published were in the third trimester of pregnancy, which could reflect reporting bias, higher risk of infection TRANS risk of infection TRANS infection MESHD or increased disease severity in late pregnancy. Seroprevalence SERO studies may allow reliable estimates of the susceptibility to infection MESHD and clinical spectrum since they include asymptomatic TRANS and mild infections not tested for PCR. We evaluated the seroprevalence SERO and clinical presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD in pregnant women in the first and third trimester. Methods: The study was approved by the Institutional Review Board at each institution and informed consent was obtained. We recruited 874 consecutive pregnancies attending for first trimester screening (10-16 weeks of gestation, n=372) or delivery (n=502) from April 14 to May 5. All women were interviewed with a structured questionnaire for COVID-19 symptoms two months prior to sampling. SARS-CoV-2 IgG and IgM/IgA antibodies were tested SERO (COVID-19 VIRCLIA Monotest, Vircell Microbiologist, Spain; reported sensitivity SERO 70% IgG and 89% IgM/IgA, and specificity 89% and 99% respectively). Indeterminate results were re-tested (VITROS Immunodiagnostic Products Anti-SARS-CoV2 Total Tests, Ortho Clinical Diagnostics, USA; 100% sensitivity SERO and specificity) and re-classified as positive or negative. Women with COVID-19 were diagnosed and managed according to standard protocols and guidelines3,4. Statistical differences were tested using the {chi}2 test or Student t-test as appropriate (p<0.05). Results: A total of 125 of 874 women (14.3%) were positive for either IgG or IgM/IgA SARS-CoV-2 antibodies SERO, 54/372 (14.5%) in the first and 71/502 (14.1%) in the third trimester. A total of 75/125 (60%) reported no symptoms of COVID-19 in the past 2 months, whereas 44 (35.2%) reported one or more symptoms, of which 31 (24.8%) had at least 3 symptoms or anosmia HP anosmia MESHD and 8 (6.4%) dyspnea HP dyspnea MESHD. Overall, 7 women (5.6%) were admitted for persistent fever HP fever MESHD despite paracetamol and dyspnea HP dyspnea MESHD, of which 3 had signs of pneumonia HP pneumonia MESHD on chest radiography. All 3 had criteria for severity (bilateral chest condensation, respiratory rate>30 and leukopenia HP leukopenia MESHD) and required oxygen support but not critical care or mechanical ventilation, and they were all discharged well. The rates of symptomatic infection MESHD, hospital admission or dyspnea HP dyspnea MESHD were significantly higher in third trimester women (Table and Figure). Discussion: The 14.3% seroprevalence SERO of SARS-COV-2 in pregnant women in this study was substantially larger than the contemporary rates of PCR positive cases (0.78%) reported for women 20-40y in Barcelona. The data confirm that COVID-19 is asymptomatic TRANS in the majority of pregnant women6 and illustrate the value of seroprevalence SERO studies to capture the high proportion of asymptomatic TRANS or mild infections MESHD. In this study, none of the 125 pregnant women with SARS-CoV-2 infection MESHD required critical care as compared to 9% reported in cases diagnosed with PCR. However, the proportion of infections MESHD with symptoms or dyspnea HP dyspnea MESHD was remarkably higher in the third trimester, and these results are in line with COVID-19 registries, reporting that 81% of hospitalized women were in late pregnancy or peripartum. These results provide reassuring information that, even in settings with a high prevalence SERO, SARS-CoV-2 infection MESHD in pregnancy mostly presents with asymptomatic TRANS or mild clinical forms. The susceptibility to infection seemed to be the same in the first and the third trimesters of gestation. The data further suggest that, as with other respiratory viruses, COVID-19 could be more severe and require increased surveillance in late pregnancy. These findings should be confirmed and extended with larger consecutive prevalence SERO studies in pregnancy.

    Afebrile patients with severe acute respiratory syndrome coronavirus 2 infection MESHD have a longer viral positivity duration: a retrospective analysis of 143 patients

    Authors: Rui Ding; Rugang Zhao; Wen Xie; Ying Fan; Ligai Liu; Ying Cao; Cheng Cheng; JingJing Wang; Qi Wang; Yanbin Wang; Ting Zhang; Minghui LI

    doi:10.21203/rs.3.rs-36961/v2 Date: 2020-06-19 Source: ResearchSquare

    Background A pandemic of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is on-going. Clinical characters of afebrile cases infected with SARS-CoV-2 remain poorly understood and informations are limited on the duration of SARS-CoV-2 viral positivity.Methods We performed a single-center retrospective study of 143 patients with SARS-CoV-2 infection MESHD in Beijing Ditan Hospital, Capital Medical University from January 26 to April 15, 2020. Differences were compared among patients with/without fever HP fever MESHD. Risk factors for the duration of SARS-CoV-2 viral positivity were evaluated.Results A total of 143 patients with positive SARS-CoV-2 test were enrolled, including 38 afebrile patients and 105 febrile patients. On admission, a total of 40 (28%) patients had leukopenia HP leukopenia MESHD, 44 (30.8%) had lymphopenia HP lymphopenia MESHD and 8 (5.6%) had thrombocytopenia HP thrombocytopenia MESHD. 78 patients (54.5%) had decreased T lymphocytes and 105 patients (73.4%) had decreased CD4+T lymphocytes. Compared with febrile cases, afebrile patients had a significantly higher white blood SERO cell count (P = 0.02), total lymphocytes (P < 0.01), platelet count (P < 0.01), T lymphocytes (P < 0.01) and CD8+ T lymphocytes (P = 0.02). The median SARS-CoV-2 viral positivity duration of these 143 patients was 14 days (IQR, 10-30 days) and for febrile and afebrile group were 13 days (IQR, 10-29 days) and 20 days (IQR, 11-31 days) respectively. Multivariate Cox regression results showed that the fever HP fever MESHD [hazard ratio (HR) = 0.49, P < 0.01]and higher count of platelet (HR = 5.47, P = 0.02) were the predominant risk factor for the SARS-CoV-2 viral positivity duration.Conclusion The SARS-CoV-2 virial positivity duration of the afebrile group was significantly longer than that in the febrile group. Fever HP Fever MESHD and a higher count of platelet were the independent protective factors for a shorter SARS-CoV-2 RNA positivity duration.

    Afebrile Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection MESHD have a Longer Viral Positivity Duration: A Retrospective Analysis of 125 Patients

    Authors: Rui Ding; Rugang Zhao; Wen Xie; Ying Fan; Ligai Liu; Ying Cao; Cheng Cheng; JingJing Wang; Qi Wang; Yanbin Wang; Ting Zhang; Minghui LI

    doi:10.21203/rs.3.rs-36961/v1 Date: 2020-06-19 Source: ResearchSquare

    Background: A pandemic of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is on-going. Clinical characters of afebrile cases infected with SARS-CoV-2 remain poorly understood and informations are limited on the duration of SARS-CoV-2 viral positivity.Methods: We performed a single-center retrospective study of 125 patients with SARS-CoV-2 infection MESHD in Beijing Ditan Hospital, Capital Medical University from January 26 to March 15, 2020. Differences were compared among patients with/without fever HP fever MESHD. Risk factors for the duration of SARS-CoV-2 viral positivity were evaluated.Results: A total of 125 patients with positive SARS-CoV-2 test were enrolled, including 38 afebrile patients and 87 febrile patients. On admission, a total of 35 (28%) patients had leukopenia HP leukopenia MESHD, 41 (32.8%) had lymphopenia HP lymphopenia MESHD and 6 (4.8%) had thrombocytopenia HP thrombocytopenia MESHD. 73 patients (58.4%) had a loss of T lymphocytes and 96 patients (76.8%) had decreased CD4+T lymphocytes. Compared with febrile cases, afebrile patients had a significantly higher white blood SERO cell count (P = 0.001), total lymphocytes (P < 0.001), platelet count (P < 0.001), T lymphocytes (P = 0.013) and CD8+ T lymphocytes (P = 0.002). The median SARS-CoV-2 viral positivity duration of these 125 patients was 14 days (IQR, 10-30 days) and for febrile and afebrile group were 12 days (IQR, 9-23 days) and 23 days (IQR, 11-30 days) respectively. Multivariate Cox regression results showed that the fever HP fever MESHD [hazard ratio (HR) = 0.497, P = 0.006], young age TRANS (HR = 0.965, P = 0.018), and higher count of platelet (HR = 4.555, P = 0.034) were the predominant risk factor for the SARS-CoV-2 viral positivity duration.Conclusion: The SARS-CoV-2 virial MESHD positivity duration of the afebrile group was significantly longer than that in the febrile group. Fever HP Fever MESHD, young age TRANS and a higher count of platelet were the independent protective factors for a shorter SARS-CoV-2 RNA positivity duration.

    Laboratory findings in coronavirus disease MESHD 2019 (COVID-19) patients: a comprehensive systematic review and meta-analysis

    Authors: Mohammad Karimian; Amirreza Jamshidbeigi; Gholamreza Badfar; Milad Azami

    doi:10.1101/2020.06.07.20124602 Date: 2020-06-08 Source: medRxiv

    Background: In early December 2019, the first patient with COVID-19 pneumonia HP pneumonia MESHD was found in Wuhan, Hubei Province, China. Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for suspected patients, which play a significant role in the diagnosis of COVID-19. Therefore, the present study was conducted to evaluate laboratory findings in COVID-19 patients. Material and methods: The present meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. This protocol is registered with the code CRD42019145410 in PROSPERO International Database. Results: Finally, 52 studies involving 5490 patients with COVID-19 entered the meta-analysis process. The prevalence SERO of leukopenia HP leukopenia MESHD, lymphopenia HP lymphopenia MESHD, elevated c-reactive protein (CRP), elevated erythrocyte sedimentation rate HP (ESR), elevated serum SERO amyloid A, elevated ferritin was estimated to be 20.9% (95%CI: 17.9-24.3), 51.6% (95%CI: 44.0-59.1), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 74.7% (95%CI: 50.0-89.7), and 72.6% (95%CI: 58.1-83.5), respectively. The prevalence SERO of elevated interleukin-6 was 59.9% (95%CI: 48.2-70.5), CD3 was 68.3% (95%CI: 50.1-82.2), reduced CD4 was 62.0% (95%CI: 51.1-71.6), reduced CD8 was 42.7% (95%CI: 32.2-53.9). The prevalence SERO of elevated troponin-I was 20.6% (95%CI: 9.0-40.5), elevated creatine kinase-MB (CKMB) was 14.7% (95%CI: 7.1-28.0), elevated brain natriuretic peptide (BNP) was 48.9% (95%CI: 30.4-67.7), elevated blood SERO urea nitrogen was 13.1% (95%CI: 6.6-24.4),, elevated creatinine was 7.2% (95%CI: 4.4-11.8), elevated lactate dehydrogenase (LDH) was 53.1% (95%CI: 43.6-62.4), hyperglycemia HP hyperglycemia MESHD was 41.1% (95% CI: 28.2-55.5), elevated total bilirubin was 48.9% (95%CI: 30.4-67.7), reduced albumin was 54.7% (95%CI: 38.1-70.2), reduced pre-albumin was 49.0% (95%CI: 26.6-71.8), and reduced PT was 53.1% (95% CI: 43.6-62.4), and D-dimer was 44.9% (95%CI: 31.0-59.6). Conclusion This study provides a comprehensive description of laboratory characteristics in patients with COVID-19. The results show that lymphopenia HP lymphopenia MESHD, elevated CRP, elevated ESR, elevated ferritin, elevated serum SERO amyloid A, elevated BNP, reduced albumin, reduced pre-albumin, reduced CD3, reduced CD4, reduced CD8, elevated D-dimer, reduced PT, elevated interleukin-2, elevated interleukin-6, elevated LDH and hyperglycemia HP hyperglycemia MESHD are the common findings at the time of admission.

    Comparison of initial HRCT features of COVID-19 pneumonia HP pneumonia MESHD and other viral pneumonias MESHD pneumonias HP

    Authors: Yilong Huang; Yuanming Jiang; Li Wu; Wenfang Yi; Jiyao Ma; Peng Wang; Ying Xie; Zhipeng Li; Xiang Li; Minchang Hong; Jialong Zhou; Chuwei Duan; Yunhui Yang; Wei Zhao; Feng Yuan; Dan Han; Bo He

    doi:10.21203/rs.3.rs-29527/v1 Date: 2020-05-17 Source: ResearchSquare

    Background: Multicenter retrospective comparison of the first high-resolution computed tomography (HRCT) findings of coronavirus disease MESHD 2019 (COVID-19) and other viral pneumonias MESHD pneumonias HP.Methods: We retrospectively collected clinical and imaging data from 254 cases of confirmed TRANS viral pneumonia MESHD pneumonia HP in 20 hospitals in Yunnan Province, China, from March 1, 2015, to March 15, 2020. According to the virus responsible for the pneumonia HP pneumonia MESHD, the pneumonias HP pneumonias MESHD were divided into non-COVID-19 (133 cases) and COVID-19 (121 cases). The non-COVID-19 pneumonias HP pneumonias MESHD included 3 types: cytomegalovirus (CMV) (31 cases), influenza A virus (82 cases), and influenza B virus (20 cases). The differences in the basic clinical characteristics, lesion distribution, location and imaging signs among the four viral pneumonias HP pneumonias MESHD were analyzed and compared.Results: Fever HP Fever MESHD and cough HP cough MESHD were the most common clinical symptoms of the four viral pneumonias HP pneumonias MESHD. Compared with the COVID-19 patients, the non-COVID-19 patients had higher proportions of fatigue HP fatigue MESHD, sore throat, expectorant and chest tightness HP chest tightness MESHD (all p<0.000). In addition, in the CMV pneumonia MESHD pneumonia HP patients, the proportion of patients with combined acquired immunodeficiency HP immunodeficiency MESHD syndrome ( AIDS MESHD) and leukopenia HP leukopenia MESHD were high (all p<0.000). Comparisons of the imaging findings of the four viral pneumonias HP pneumonias MESHD showed that pulmonary lesions of COVID-19 were more likely to occur in the peripheral and lower lobes of both lungs, while those of CMV pneumonia MESHD pneumonia HP were diffusely distributed. Compared with the non-COVID-19 pneumonias HP pneumonias MESHD, COVID-19 pneumonia HP pneumonia MESHD was more likely to present as ground-glass opacity (GGO), intralobular interstitial thickening HP, vascular thickening and halo sign (all p<0.05). In addition, in the early stage of COVID-19, extensive consolidation, fibrous stripes, subpleural lines, crazy-paving pattern, tree-in-bud HP, mediastinal lymphadenectasis, pleural thickening HP pleural thickening MESHD and pleural effusion HP pleural effusion MESHD were rare (all p<0.05).Conclusion: The HRCT findings of COVID-19 pneumonia HP pneumonia MESHD and other viral pneumonias MESHD pneumonias HP overlapped significantly, but many important differential imaging features could still be observed.

    Severe Acute Respiratory Syndrome Coronavirus 2 Infection MESHD in Patients Living with Human Immunodeficiency Virus MESHD Immunodeficiency HP Virus: Case Reports and Review of the Literature

    Authors: Liping Chen; Fang Xiao; Li Cao; Meng Xie; Yue Wen; Zhicheng Zhang; Qiang Ding; Wei Yan; Dean Tian; Ge Wang

    doi:10.21203/rs.3.rs-28578/v1 Date: 2020-05-11 Source: ResearchSquare

    Background: Novel coronavirus pneumonia MESHD pneumonia HP (COVID-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) has rapidly spread over the globe. The knowledge about SARS-CoV-2 infection MESHD in immunocompromised patients was limited. Case presentation: We presented here two human immunodeficiency HP immunodeficiency MESHD virus (HIV)-infected cases with laboratory confirmed COVID-19 and clinically confirmed COVID-19, respectively. The patients both presented with fever HP fever MESHD at illness onset and patchy shadows in radiological images of lungs. Laboratory findings revealed leukopenia HP leukopenia MESHD, lymphopenia HP lymphopenia MESHD and positive anti-HIV antibody SERO. The younger case had a moderate course and was discharged after a 28-day hospitalization. However, the elder case with multiple comorbidities developed dyspnea HP dyspnea MESHD and died on the fourth day after admission. Conclusions: Combining our data with two case reports, we summarize that disease course varies in HIV-infected MESHD patients with COVID-19. More attention should be paid to the management of these patients. Whether there is any difference about clinical characteristics and prognosis of COVID-19 between HIV-infected and non-HIV infected MESHD patients, remains to be further investigated.

    Clinical and CT manifestations of coronavirus disease MESHD 2019 (COVID-19): comparison of suspected cases of COVID-19 in isolation and non-COVID-19 pneumonia HP pneumonia MESHD in a single-center study conducted in Beijing, China

    Authors: Heng Liu; Weihua Li; Lei Zhang; Bing Liu; Chaoying Qi; Wei Fan; Pei Feng; Jingjing Pan; Fengyuan Man

    doi:10.21203/rs.3.rs-27288/v1 Date: 2020-05-06 Source: ResearchSquare

    Background: The clinical and CT manifestations of COVID-19 pneumonia HP pneumonia MESHD and non-COVID-19 pneumonia HP pneumonia MESHD in the same period have not been compared in detail. The purpose of this study is to analyze the clinical and CT manifestations of COVID-19 pneumonia HP pneumonia MESHD and perform a comparison of those isolated patients for presumed COVID-19 infection MESHD and of non-COVID-19 pneumonia HP pneumonia MESHD in the same period.Methods: 173 patients with pneumonia HP pneumonia MESHD from January 1, 2020 to March 20, 2020 were retrospectively enrolled and classified into three groups: patients with COVID-19 pneumonia HP pneumonia MESHD (Group I, N=4), patients in hospital-isolation for presumed COVID-19 pneumonia HP pneumonia MESHD (Group Ⅱ, N=5), and patients with non-COVID-19 pneumonia HP pneumonia MESHD (Group III, N=163). Clinical symptoms, laboratory test results and CT imaging features were compared among three groups.Results: Fever HP Fever MESHD and cough HP cough MESHD were the most common clinical symptoms in the three groups. 30/163 (18.4%) patients were asymptomatic TRANS in Group III. Leukopenia HP Leukopenia MESHD, lymphocytopenia MESHD, and elevated C-reactive protein was identified in 1 (25%), 1 (25%), and 1 (25%) patient in Group I; 1 (20%), 1 (20%), and 2 (40%) patients in Group II; 10/157 (6.4%), 33/157(21.0%), and 94/136 (69.1%) patients in Group III. Demarcated GGO/mixed GGO, ill-defined GGO/mixed GGO, consolidation, centrilobular nodule, tree-in bud opacity, bilateral involvement, peripheral distribution, posterior part/lower lobe predilection was observed in 3/4 (75%), 2/4 (50%), 4/4 (100%), 2/4 (50%), 0, 3/4 (75%), 3/4 (75%), and 2/4 (50%) patients, respectively in Group I; 1/5 (20%), 5/5 (100%), 4/5 (80%), 4/5 (80%), 3/5 (60%), 4/5 (80%), 2/5 (40%), and 3/5 (60%) patients in Group Ⅱ; 1/163 (0.6%), 87/163 (54.3%), 115/163 (70.6%), 117/163 (71.8%), 95/163 (58.3%), 52/163 (31.9%), 9/163 (5.5%), and 9/163 (5.5%) patients in Group III, respectively.Conclusions: Demarcated GGO and consolidation prefer the diagnosis of COVID-19 pneumonia HP pneumonia MESHD, whereas ill-defined GGO and consolidation, centrilobular nodule surrounded by GGO, and tree-in-bud opacity are preferred for non-COVID-19 pneumonia HP pneumonia MESHD. chest CT has potential in early identification of COVID-19 and implementation of isolation for appropriate case.

    Hydroxychloroquine-Induced Stevens-Johnson Syndrome MESHD in COVID-19: A rare Case Report

    Authors: Lotfollah Davoodi; Hamed Jafarpour; Armaghan Kazeminejad; Eissa Soleymani; Zahra Akbari; Alireza Razavi

    doi:10.21203/rs.3.rs-26196/v1 Date: 2020-04-29 Source: ResearchSquare

    Background: The international outbreak of respiratory illness MESHD termed coronavirus disease MESHD 2019 (COVID-19) began in December 2019 that has affected more than 0.8 million individuals. To date, there are no specific therapeutic agents for coronavirus infections MESHD. One of the drugs that have an effective role in improving the condition of patients with COVID-19 is hydroxychloroquine (HCQ). This drug is not a definitive treatment for this disease and has a supportive role. Like all medications, HCQ has side effects and may occur in COVID-19 patients. Stevens-Johnson syndrome MESHD caused by HCQ is very rare.Case presentation: A 42-year-old woman, presented with fever HP fever MESHD and dry cough MESHD cough HP in the past two days to her family physician. Lab tests revealed elevated lactate dehydrogenase (LDH, 648 units/liter (U/L)), C-reactive protein level (CRP, 52 milligrams/Liter (mg/L), normal: <10 mg/L), aspartate aminotransferase (AST, 59 U/L, normal: 10-40 U/L), thrombocytopenia HP thrombocytopenia MESHD, and leukopenia HP leukopenia MESHD. Mild bilateral patchy ground-glass opacity was seen in lung CT-Scan. Due to COVID-19 pandemic and clinical findings, the nasopharyngeal swab test was done and SARS-CoV-2 nucleic acid was detected by RT-PCR. HCQ 200 mg twice daily was started. After two days, the patient presented with a pruritic erythematous maculopapular rash MESHD and flat atypical targets that started from the distal of upper extremities MESHD and rapidly, involved the entire body, and torn blisters which were only be seen as ulcers MESHD on orolabial area. The Nikolsky sign was positive. Due to the likelihood of a drug reaction, HCQ was discontinued, and COVID-19 treatment was changed to lopinavir/ritonavir (LPV/RTV) 400 mg twice daily. Finally, she was discharged after five days with nonpruritic scalded skin on the distal of upper extremities. Conclusions: It is worth noting that although HCQ appears to be safe and has mild side effects, however, the boundary between therapeutic and toxic doses is narrow and severe disorders of their use can life-threatening. One of the side effects of HCQ is SJS caused by the drug, and given the worldwide pandemic of COVID-19 and the increasing need for this drug, we need to be careful about its use in order to control and manage the side effects of this drug. 

    Flight of the COVID-19 patient: experience with aWuhan evacuee- a case report

    Authors: Sandeep Segar; Daniel Bouland; Francesca Torriani; Kevin Kwak; Deepak Asudani; Randy Taplitz; Vineet Gupta

    doi:10.21203/rs.3.rs-24578/v1 Date: 2020-04-22 Source: ResearchSquare

    Background:Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), was declared a global pandemic by World Health Organization in March 2020. Case Presentation:We report a case of a 51-year-old Chinese woman who was evacuated from Wuhan, China and diagnosed with COVID-19 infection MESHD at a Southern California quarantine facility. Clinical course was notable for high fevers HP, night sweats HP, productive cough HP, transient leukopenia HP leukopenia MESHD, lymphopenia HP lymphopenia MESHD, thrombocytopenia HP thrombocytopenia MESHD, and transaminitis. Evolving hypoxia MESHD and infiltrates on chest imaging warranted the trial of an investigational antiviral drug - remdesivir. The patient recovered and was discharged after two weeks of hospitalization. Conclusion:This case highlights the patient’s clinical course including diagnostic work-up, medical management, and challenges in defining non-infectivity in a relatively unknown disease.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.